Search Results 51-60 of 26446 for 1-(2-desoxi-2-fluoro-β-D-arabinofuranosil)-uracilo
Langford B, D'Souza RS, Pingree M, Mauck WD. ... 2015 Jun 10; 564 (1):1-8 Epub 2015 Mar 19. View PubMed; Gazelka ... 2015; 19(1-2):32-7. Epub 1900 Jan 01. Moeschler ...
2024 Mar; 2 (1) Epub 2024 Jan 09. View PubMed; Gupta VK, Rajendraprasad S, Ozkan M, Ramachandran D, Ahmad S, Bakken JS, Laudanski K, Gajic O, Bauer B, Zec S ...
2012 Oct; 1(7):1169-71. View PubMed; Vuk-Pavlovic S. Towards systems based immunotherapy of cancer. Period Biol. 2012 Jun; 114(2):187-99.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. Precautions. Portions of this document last ...
Descriptions. SARS-CoV-2 vaccine, mRNA (Pfizer) is under investigation as an active immunization against COVID-19 caused by the SARS- ...
... (1) the role of β-amyloid (Aβ) in Alzheimer's disease (AD) and (2) the structure and catalytic properties of the enzyme acetylcholinesterase (AChE). ... D., is an ...
... 1/2 study published in the journal Lancet Oncology. ... B., and Vivek Roy, M.D., of Mayo Clinic; Jesus Berdeja ... D., Alessandra Di Bacco, Ph.D., Jose Estevam, B ...
2019 Jan 1; 21 (1):26-36. View PubMed; Alexander BM, Trippa ... Phase 1/2 trial of temsirolimus and sorafenib in ... D'Assoro A, Friday B, Galanis E. Alisertib ...
Mayo Clinic researcher Keith M. Furutani, Ph.D., studies emerging technologies in radiation therapy, especially carbon ion radiation therapy.
2019 Feb 1; 60 (2):779-786. View PubMed; Roy Chowdhury U, Dosa PI, Fautsch MP. ATP sensitive potassium channel openers: A new class of ocular hypotensive ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be part of the cutting-edge research and care that's changing medicine.